Allogene Therapeutics(ALLO)
icon
搜索文档
Allogene Therapeutics(ALLO) - 2020 Q1 - Quarterly Report
2020-05-07 04:18
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________________ FORM 10-Q ________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 ...
Allogene Therapeutics(ALLO) - 2019 Q4 - Annual Report
2020-02-28 05:07
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________ FORM 10-K _________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38693 _________________________________ Allogen ...
Allogene Therapeutics(ALLO) - 2019 Q4 - Earnings Call Transcript
2020-02-28 03:34
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2019 Earnings Conference Call February 27, 2020 8:30 AM ET Company Participants Christine Cassiano – Chief Communications Officer David Chang – President and Chief Executive Officer Raphael Amado – Executive Vice President of Research and Development and Chief Medical Officer Eric Schmidt – Chief Financial Officer Conference Call Participants Marc Frahm – Cowen and Company Salveen Richter – Goldman Sachs Biren Amin – Jefferies Tyler Van Buren – Piper Sandler Mark ...
Allogene Therapeutics(ALLO) - 2019 Q3 - Quarterly Report
2019-11-06 05:02
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________________ FORM 10-Q ________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe ...
Allogene Therapeutics(ALLO) - 2019 Q3 - Earnings Call Transcript
2019-11-06 03:57
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2019 Earnings Conference Call November 5, 2019 8:30 AM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President and Chief Executive Officer Rafael Amado - Executive Vice President of Research and Development and Chief Medical Officer Eric Schmidt - Chief Financial Officer Conference Call Participants Biren Amin - Jefferies & Company, Inc. Philip Nadeau - Cowen and Company Tyler Van Buren - Piper Jaffray Amanda Murphy - BTI ...
Allogene Therapeutics(ALLO) - 2019 Q2 - Quarterly Report
2019-08-08 04:22
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________________ FORM 10-Q ________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 ...